Nonviral gene therapy approaches to hemophilia

Andrew Gómez-Vargas, Gonzalo Hortelano

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The goal of hemophilia gene therapy is to obtain long-term therapeutic levels of factor VIII (FVIII) or factor IX (FIX) without stimulating an immune response against the transgene product or the vector. The success of gene therapy is largely dependent on the development of appropriate gene delivery vectors. Both viral vectors and nonviral vectors have been considered for the development of hemophilia gene therapy. In general, viral vectors are far more efficient than nonviral gene delivery approaches and resulted in long-term therapeutic levels of FVIII or FIX in preclinical animal models. However, there are several reasons why a nonviral treatment would still be desirable, particularly because some viral vectors are associated with inflammatory reactions, that render transgene expression transient, or with an increased risk of insertional oncogenesis when random integrating vectors are used. Nonviral vectors may obviate some of these concerns. Since nonviral vectors are typically assembled in cell-free systems from well-defined components, they have significant manufacturing advantages over viral vectors. The continued development of improved nonviral gene delivery approaches offers new perspectives for gene therapy of chronic diseases including hemophilia.

Original languageEnglish
Pages (from-to)197-204
Number of pages8
JournalSeminars in Thrombosis and Hemostasis
Volume30
Issue number2
DOIs
Publication statusPublished - Apr 2004
Externally publishedYes

Fingerprint

Hemophilia A
Genetic Therapy
Factor IX
Factor VIII
Transgenes
Genes
Cell-Free System
Carcinogenesis
Chronic Disease
Therapeutics
Animal Models

Keywords

  • Gene therapy
  • Hemophilia
  • Immunoisolation
  • Nonviral
  • Plasmid
  • Recombinant cells

ASJC Scopus subject areas

  • Hematology

Cite this

Nonviral gene therapy approaches to hemophilia. / Gómez-Vargas, Andrew; Hortelano, Gonzalo.

In: Seminars in Thrombosis and Hemostasis, Vol. 30, No. 2, 04.2004, p. 197-204.

Research output: Contribution to journalArticle

@article{305d8fff84e94d55a164025abc5c17af,
title = "Nonviral gene therapy approaches to hemophilia",
abstract = "The goal of hemophilia gene therapy is to obtain long-term therapeutic levels of factor VIII (FVIII) or factor IX (FIX) without stimulating an immune response against the transgene product or the vector. The success of gene therapy is largely dependent on the development of appropriate gene delivery vectors. Both viral vectors and nonviral vectors have been considered for the development of hemophilia gene therapy. In general, viral vectors are far more efficient than nonviral gene delivery approaches and resulted in long-term therapeutic levels of FVIII or FIX in preclinical animal models. However, there are several reasons why a nonviral treatment would still be desirable, particularly because some viral vectors are associated with inflammatory reactions, that render transgene expression transient, or with an increased risk of insertional oncogenesis when random integrating vectors are used. Nonviral vectors may obviate some of these concerns. Since nonviral vectors are typically assembled in cell-free systems from well-defined components, they have significant manufacturing advantages over viral vectors. The continued development of improved nonviral gene delivery approaches offers new perspectives for gene therapy of chronic diseases including hemophilia.",
keywords = "Gene therapy, Hemophilia, Immunoisolation, Nonviral, Plasmid, Recombinant cells",
author = "Andrew G{\'o}mez-Vargas and Gonzalo Hortelano",
year = "2004",
month = "4",
doi = "10.1055/s-2004-825633",
language = "English",
volume = "30",
pages = "197--204",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Nonviral gene therapy approaches to hemophilia

AU - Gómez-Vargas, Andrew

AU - Hortelano, Gonzalo

PY - 2004/4

Y1 - 2004/4

N2 - The goal of hemophilia gene therapy is to obtain long-term therapeutic levels of factor VIII (FVIII) or factor IX (FIX) without stimulating an immune response against the transgene product or the vector. The success of gene therapy is largely dependent on the development of appropriate gene delivery vectors. Both viral vectors and nonviral vectors have been considered for the development of hemophilia gene therapy. In general, viral vectors are far more efficient than nonviral gene delivery approaches and resulted in long-term therapeutic levels of FVIII or FIX in preclinical animal models. However, there are several reasons why a nonviral treatment would still be desirable, particularly because some viral vectors are associated with inflammatory reactions, that render transgene expression transient, or with an increased risk of insertional oncogenesis when random integrating vectors are used. Nonviral vectors may obviate some of these concerns. Since nonviral vectors are typically assembled in cell-free systems from well-defined components, they have significant manufacturing advantages over viral vectors. The continued development of improved nonviral gene delivery approaches offers new perspectives for gene therapy of chronic diseases including hemophilia.

AB - The goal of hemophilia gene therapy is to obtain long-term therapeutic levels of factor VIII (FVIII) or factor IX (FIX) without stimulating an immune response against the transgene product or the vector. The success of gene therapy is largely dependent on the development of appropriate gene delivery vectors. Both viral vectors and nonviral vectors have been considered for the development of hemophilia gene therapy. In general, viral vectors are far more efficient than nonviral gene delivery approaches and resulted in long-term therapeutic levels of FVIII or FIX in preclinical animal models. However, there are several reasons why a nonviral treatment would still be desirable, particularly because some viral vectors are associated with inflammatory reactions, that render transgene expression transient, or with an increased risk of insertional oncogenesis when random integrating vectors are used. Nonviral vectors may obviate some of these concerns. Since nonviral vectors are typically assembled in cell-free systems from well-defined components, they have significant manufacturing advantages over viral vectors. The continued development of improved nonviral gene delivery approaches offers new perspectives for gene therapy of chronic diseases including hemophilia.

KW - Gene therapy

KW - Hemophilia

KW - Immunoisolation

KW - Nonviral

KW - Plasmid

KW - Recombinant cells

UR - http://www.scopus.com/inward/record.url?scp=2342597890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342597890&partnerID=8YFLogxK

U2 - 10.1055/s-2004-825633

DO - 10.1055/s-2004-825633

M3 - Article

C2 - 15118931

AN - SCOPUS:2342597890

VL - 30

SP - 197

EP - 204

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 2

ER -